Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.
Arnold MB, et al. Among authors: burke l.
Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.
Rheumatology (Oxford). 2018.
PMID: 29077900
Free PMC article.
Clinical Trial.